

Pedram Heidari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/661916/publications.pdf>

Version: 2024-02-01

32
papers

2,350
citations

623734

14
h-index

434195

31
g-index

32
all docs

32
docs citations

32
times ranked

5152
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of Thin Film Deposition on AFM Cantilever Tips in Adhesion and Young's Modulus of MEMS Surfaces. <i>Materials</i> , 2022, 15, 2102.	2.9	7
2	Hyperpolarized [1-13C]Pyruvate Magnetic Resonance Spectroscopic Imaging for Evaluation of Early Response to Tyrosine Kinase Inhibition Therapy in Gastric Cancer. <i>Molecular Imaging and Biology</i> , 2022, 1.	2.6	4
3	Immune Checkpoint Inhibitor-Mediated Cancer Theranostics with Radiolabeled Anti-Granzyme B Peptide. <i>Pharmaceutics</i> , 2022, 14, 1460.	4.5	2
4	An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1522-1537.	6.4	6
5	Impact of 18F-FDG PET/MR based tumor delineation in radiotherapy planning for cholangiocarcinoma. <i>Abdominal Radiology</i> , 2021, 46, 3908-3916.	2.1	2
6	Electromagnetic Tracking and Optical Molecular Imaging Guidance for Liver Biopsy and Point-of-Care Tissue Assessment in Phantom and Woodchuck Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1439-1447.	2.0	2
7	Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective. <i>Frontiers in Oncology</i> , 2021, 11, 722277.	2.8	5
8	Non-invasive Detection of Immunotherapy-Induced Adverse Events. <i>Clinical Cancer Research</i> , 2021, 27, 5353-5364.	7.0	13
9	Artificial Intelligence and the Future of Diagnostic and Therapeutic Radiopharmaceutical Development. <i>PET Clinics</i> , 2021, 16, 513-523.	3.0	15
10	Theoretical and Experimental Analysis of Surface Roughness and Adhesion Forces of MEMS Surfaces Using a Novel Method for Making a Compound Sputtering Target. <i>Coatings</i> , 2021, 11, 1551.	2.6	14
11	Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 105-114.	6.4	16
12	Comparative accuracy of qualitative and quantitative 18F-FDG PET/CT analysis in detection of lymph node metastasis from anal cancer. <i>Abdominal Radiology</i> , 2019, 44, 828-835.	2.1	7
13	Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis. , 2019, 7, 356.		29
14	Optical imaging with a novel cathepsin-activatable probe for enhanced detection of colorectal cancer. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 9, 230-242.	1.0	5
15	C11 Methionine PET (MET-PET) Imaging of Glioblastoma for Detecting Postoperative Residual Disease and Response to Chemoradiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1024-1028.	0.8	18
16	Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions. <i>Theranostics</i> , 2018, 8, 3380-3391.	10.0	11
17	Development and characterization of a bioglass/chitosan composite as an injectable bone substitute. <i>Carbohydrate Polymers</i> , 2017, 157, 1261-1271.	10.2	50
18	A phase one, single-dose, open-label, clinical safety and PET/MR imaging study of Ga-DOTATOC in healthy volunteers. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 7, 53-62.	1.0	2

#	ARTICLE	IF	CITATIONS
19	Pilot Clinical Trial of Indocyanine Green Fluorescence-Augmented Colonoscopy in High Risk Patients. Gastroenterology Research and Practice, 2016, 2016, 1-7.	1.5	4
20	Optical Imaging of Mesenchymal Epithelial Transition Factor (MET) for Enhanced Detection and Characterization of Primary and Metastatic Hepatic Tumors. Theranostics, 2016, 6, 2028-2038.	10.0	15
21	Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance. Journal of Nuclear Medicine, 2016, 57, 1413-1419.	5.0	28
22	Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer. Technology in Cancer Research and Treatment, 2016, 15, 234-242.	1.9	17
23	Design, construction and testing of a low-cost automated (68)Gallium-labeling synthesis unit for clinical use. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 176-84.	1.0	6
24	Pharmacodynamic Imaging Guides Dosing of a Selective Estrogen Receptor Degradar. Clinical Cancer Research, 2015, 21, 1340-1347.	7.0	32
25	Imaging of Secreted Extracellular Periostin, an Important Marker of Invasion in the Tumor Microenvironment in Esophageal Cancer. Journal of Nuclear Medicine, 2015, 56, 1246-1251.	5.0	17
26	The Role of Ultrasound in Diagnosis of the Causes of Low Back Pain: a Review of the Literature. Asian Journal of Sports Medicine, 2015, 6, e23803.	0.3	33
27	PET imaging of glioblastoma multiforme EGFR expression for therapeutic decision guidance. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 379-89.	1.0	10
28	Fluorescent Nanoparticle Imaging Allows Noninvasive Evaluation of Immune Cell Modulation in Esophageal Dysplasia. Molecular Imaging, 2014, 13, 7290.2014.00003.	1.4	12
29	An EGFR Targeted PET Imaging Probe for the Detection of Colonic Adenocarcinomas in the Setting of Colitis. Theranostics, 2014, 4, 893-903.	10.0	29
30	Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. Cancer Cell, 2014, 25, 719-734.	16.8	1,892
31	Optical Imaging of Periostin Enables Early Endoscopic Detection and Characterization of Esophageal Cancer in Mice. Gastroenterology, 2013, 144, 294-297.	1.3	28
32	Free Somatostatin Receptor Fraction Predicts the Antiproliferative Effect of Octreotide in a Neuroendocrine Tumor Model: Implications for Dose Optimization. Cancer Research, 2013, 73, 6865-6873.	0.9	19